Mydecine Innovations Group, a publicly traded pre-revenue biopharmaceutical company, launched in early 2020 with collaborators and staff members throughout North America and Europe. Mydecine was founded to offer healthcare professionals a variety of better serotonin-modulating medications by developing novel drug families derived from Psilocybin and MDMA. Pairing modern pharmaceutical chemistry and technology with these psychedelic compounds allows the Company to evolve these medications to increase patient effectiveness and safety and make them more accessible to practitioners. The Company is developing several prodrug families, starting with a psilocybin-derived smoking cessation treatment in a NIDA-funded Johns Hopkins University study. Mydecine's primary focus is developing MYCO-006, MDMA-derived short-acting analogs that could be utilized for various indications such as pain and anxiety. Mydecine uses advanced AI and pharma research infrastructure within the University of Alberta to continuously generate a new wave of pharmaceuticals that will be more inexpensive, safer, effective, and accessible to the public after FDA approval. The team is passionate about its mission and commitment to making a healthy difference in people’s lives.